CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 80,676,509	$ 23,065,344
Cost of Revenue	47,118,189	8,195,735
Gross profit	33,558,320	14,869,609
Operating expenses
Sales and marketing	10,376,003	5,116,868
Distribution costs	12,369,903	2,214,322
General and administrative expenses	9,546,188	9,141,667
Share-based compensation	3,664,538	3,331,586
Amortization of acquired intangible assets	4,208,991	979,988
Depreciation	944,704	574,309
Operating expenses	41,110,327	21,358,740
Loss from operations	(7,552,007)	(6,489,131)
Interest (expense) income, net	(4,761,903)	(202,120)
Change in derivative liability	1,770	(3,293)
Loss on sale of Infusionz and select assets	(2,212,542)	0
Impairment of Interactive Offers intangible assets	(3,746,301)	0
Gain on sale of property and equipment	0	5,500
Lease impairment, California facility	(200,512)	0
Gain on SBA PPP loan extinguishment	0	300,995
Other (expense) income, net	(10,919,488)	101,082
Net loss before income tax	(18,471,495)	(6,388,049)
Income tax benefit	3,049,293	518,398
Net loss from continuing operations	(15,422,202)	(5,869,651)
(Loss) income from discontinued operations - Interactive Offers	$ (1,729,636)	$ (1,160,160)
(Loss) income from discontinued operations - Infusionz	$ (338,418)	$ 4,983,781
Net loss (income) attributable to non-controlling interest	$ 559,967	$ (54,820)
Net (loss) income attributable to Upexi, Inc.	$ (16,930,289)	$ (2,100,850)
Basic income (loss) per share:
Loss per share from continuing operations	$ (0.86)	$ (0.36)
Income per share from discontinued operations	(0.10)	(0.07)
Total income (loss) per share	(0.96)	(0.43)
Loss per share from continuing operations	(0.86)	(0.36)
Total income (loss) per share	$ (0.96)	$ (0.43)
Basic weighted average shares outstanding	17,877,959	16,224,520
Fully diluted weighted average shares outstanding	17,877,959	16,224,520